AR097193A1 - Comprimidos farmacéuticos que comprenden ácido acetilsalicílico y clopidogrel - Google Patents
Comprimidos farmacéuticos que comprenden ácido acetilsalicílico y clopidogrelInfo
- Publication number
- AR097193A1 AR097193A1 ARP140102898A ARP140102898A AR097193A1 AR 097193 A1 AR097193 A1 AR 097193A1 AR P140102898 A ARP140102898 A AR P140102898A AR P140102898 A ARP140102898 A AR P140102898A AR 097193 A1 AR097193 A1 AR 097193A1
- Authority
- AR
- Argentina
- Prior art keywords
- core
- clopidogrel
- gastro
- pharmaceutically acceptable
- acetylsalicylic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Un comprimido farmacéutico que comprende un núcleo y una capa externa, comprendiendo el núcleo ácido acetilsalicílico o una de sus sales farmacéuticamente aceptables y comprendiendo la capa externa clopidogrel o una de sus sales farmacéuticamente aceptables, estando separado el núcleo de la capa externa por un recubrimiento de tres capas compuesto de una capa gastrorresistente insertada entre dos capas aislantes, comprendiendo la capa gastrorresistente al menos un polímero gastrorresistente y al menos 40% en peso de talco, con respecto al peso del polímero gastrorresistente. Reivindicación 4: El comprimido según una cualquiera de las reivindicaciones precedentes, en el que la composición de las capas aislantes es idéntica y comprende hidroxipropilmetilcelulosa (HPMC), hidroxipropilcelulosa y/o alcohol polivinílico. Reivindicación 5: El comprimido según una cualquiera de las reivindicaciones precedentes, en el que el clopidogrel y el ácido acetilsalicílico están presentes en una relación molar de clopidogrel / ácido acetilsalicílico entre 0,35 y 0,45. Reivindicación 6: Un procedimiento para fabricar un comprimido según una cualquiera de las reivindicaciones 1 a 5, comprendiendo dicho procedimiento las siguientes etapas:(i) preparar un núcleo que comprende ácido acetilsalicílico o una de sus sales farmacéuticamente aceptables, (ii) recubrir el núcleo, de modo que se obtenga un núcleo recubierto, con un recubrimiento de tres capas compuesto de una capa gastrorresistente insertada entre dos capas aislantes, (iii) recubrir por compresión el núcleo recubierto obtenido en la etapa (ii) con el polvo que comprende el clopidogrel o una de sus sales farmacéuticamente aceptables, para obtener de este modo un comprimido. Reivindicación 13: El comprimido según una cualquiera de las reivindicaciones 1 a 5, para uso en el tratamiento de una condición patológica inducida por agregación plaquetaria, incluyendo angina estable o inestable, trastornos del sistema cardiovascular y cerebrovascular, por ejemplo trastornos tromboembólicos asociados con ateroesclerosis y con diabetes, tales como angina inestable, ictus, restenosis post-angioplastia, endarterectomía o la inserción de prótesis endovasculares metálicas, otrastornos tromboembólicos asociados con la re-trombosis post-trombolisis, con el infarto, con la demencia de origen isquémico, con enfermedades arteriales periféricas, con hemodiálisis, con fibrilación auricular, o también durante el uso de prótesis vasculares, de derivaciones aortocoronarias, o también durante la radioterapia con el fin de reducir los efectos secundarios de la misma.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/FR2013/051874 WO2015015062A1 (fr) | 2013-08-02 | 2013-08-02 | Comprime pharmaceutique comprenant de l'acide acetylsalicylique et du clopidogrel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR097193A1 true AR097193A1 (es) | 2016-02-24 |
Family
ID=49085055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140102898A AR097193A1 (es) | 2013-08-02 | 2014-08-01 | Comprimidos farmacéuticos que comprenden ácido acetilsalicílico y clopidogrel |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP3027176B1 (es) |
| JP (1) | JP5905165B2 (es) |
| KR (1) | KR102243349B1 (es) |
| CN (1) | CN105407877B (es) |
| AR (1) | AR097193A1 (es) |
| BR (1) | BR112016001822B1 (es) |
| CL (1) | CL2016000143A1 (es) |
| CR (1) | CR20160067A (es) |
| DO (1) | DOP2016000024A (es) |
| ES (1) | ES2648913T3 (es) |
| HK (1) | HK1221649A1 (es) |
| MY (1) | MY176793A (es) |
| PE (1) | PE20160212A1 (es) |
| PH (1) | PH12016500121B1 (es) |
| SG (1) | SG11201600218SA (es) |
| TW (1) | TWI642435B (es) |
| WO (2) | WO2015015062A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104800183B (zh) * | 2015-04-14 | 2016-08-31 | 陕西必康制药集团控股有限公司 | 一种阿司匹林肠溶片及其制备方法和应用 |
| CN108289849A (zh) * | 2015-06-26 | 2018-07-17 | 韩国联合制药株式会社 | 莫沙必利与雷贝拉唑的复合制剂 |
| WO2017037741A1 (en) * | 2015-09-02 | 2017-03-09 | Sun Pharmaceutical Industries Ltd | Compact solid dosage form of aspirin and clopidogrel |
| CN107308157B (zh) * | 2017-06-08 | 2020-02-21 | 广州白云山天心制药股份有限公司 | 一种含有氯吡格雷的复方口服固体制剂及其制备方法 |
| WO2019030610A1 (en) * | 2017-08-11 | 2019-02-14 | Solutions In Innovative Research Pvt. Ltd. | PHARMACEUTICAL COMPOSITIONS WITH DUAL DIRECTLY COMPRESSIBLE MEDICAMENT RELEASE |
| CN107669690A (zh) * | 2017-10-23 | 2018-02-09 | 罗铭炽 | 一种含阿司匹林和氯吡格雷的片剂 |
| CN107693524A (zh) * | 2017-10-23 | 2018-02-16 | 罗铭炽 | 一种含阿司匹林和氯吡格雷的制备方法 |
| CN109528668A (zh) * | 2018-12-20 | 2019-03-29 | 华中药业股份有限公司 | 阿司匹林片及其制备方法 |
| CN112587495A (zh) * | 2020-12-14 | 2021-04-02 | 乐普药业股份有限公司 | 一种阿司匹林和硫酸氢氯吡格雷复方制剂及其制备方法 |
| EP4091605A1 (en) | 2021-05-19 | 2022-11-23 | G.L. Pharma GmbH | Pharmaceutical tablet comprising acetylsalicylic acid |
| CN115212180B (zh) * | 2022-09-03 | 2024-05-10 | 深圳市信宜特科技有限公司 | 一种阿司匹林和硫酸氢氯吡格雷的复方制剂及其制备方法 |
| KR20240050841A (ko) * | 2022-10-12 | 2024-04-19 | 일양약품주식회사 | 클로피도그렐 및 일라프라졸을 포함하는 복합제제 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04346930A (ja) * | 1991-05-25 | 1992-12-02 | Sumitomo Pharmaceut Co Ltd | 安定なアスピリン腸溶錠 |
| FR2744918B1 (fr) | 1996-02-19 | 1998-05-07 | Sanofi Sa | Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique |
| FR2779726B1 (fr) | 1998-06-15 | 2001-05-18 | Sanofi Sa | Forme polymorphe de l'hydrogenosulfate de clopidogrel |
| FR2792836B3 (fr) * | 1999-04-30 | 2001-07-27 | Sanofi Sa | Composition pharmaceutique sous forme unitaire contenant de l'aspirine et de l'hydrogenosulfate de clopidogrel |
| CN101703513B (zh) * | 2009-11-10 | 2014-04-23 | 沈阳药科大学 | 阿司匹林和氯吡格雷或其药学上可接受的盐的复方缓释制剂 |
| CA2792232C (en) * | 2010-03-11 | 2014-07-15 | Wockhardt Limited | A device for the manufacture of a dosage form with a hole and method of manufacture |
| CN101874786B (zh) * | 2010-06-05 | 2012-04-25 | 浙江金华康恩贝生物制药有限公司 | 无溶剂挤出滚圆法制备阿司匹林肠溶制剂 |
| KR20120068277A (ko) * | 2010-12-17 | 2012-06-27 | 한미사이언스 주식회사 | ＨＭＧ－ＣｏＡ 환원효소 억제제 및 아스피린을 포함하는 약제학적 복합제제 |
| EP2755641A4 (en) * | 2011-09-14 | 2015-03-18 | Pozen Inc | CONTROLLED DOSAGE OF CLOPIDOGREL IN MAGIC ACID INHIBITION THERAPIES |
| KR101675501B1 (ko) * | 2011-11-02 | 2016-11-14 | 한국유나이티드제약 주식회사 | 클로피도그렐 및 아스피린의 복합제제 |
| KR101473268B1 (ko) * | 2012-03-09 | 2014-12-16 | 주식회사유한양행 | 클로피도그렐과 아스피린을 포함하는 약학 조성물 및 그의 제조방법 |
-
2013
- 2013-08-02 JP JP2015529093A patent/JP5905165B2/ja active Active
- 2013-08-02 WO PCT/FR2013/051874 patent/WO2015015062A1/fr active Application Filing
-
2014
- 2014-07-25 BR BR112016001822-2A patent/BR112016001822B1/pt active IP Right Grant
- 2014-07-25 PE PE2016000120A patent/PE20160212A1/es unknown
- 2014-07-25 WO PCT/EP2014/066110 patent/WO2015014766A1/en active Application Filing
- 2014-07-25 SG SG11201600218SA patent/SG11201600218SA/en unknown
- 2014-07-25 KR KR1020167004776A patent/KR102243349B1/ko active IP Right Grant
- 2014-07-25 MY MYPI2016700042A patent/MY176793A/en unknown
- 2014-07-25 CN CN201480042849.3A patent/CN105407877B/zh active Active
- 2014-07-25 EP EP14753025.7A patent/EP3027176B1/en active Active
- 2014-07-25 ES ES14753025.7T patent/ES2648913T3/es active Active
- 2014-08-01 AR ARP140102898A patent/AR097193A1/es unknown
- 2014-08-01 TW TW103126491A patent/TWI642435B/zh active
-
2016
- 2016-01-19 PH PH12016500121A patent/PH12016500121B1/en unknown
- 2016-01-19 DO DO2016000024A patent/DOP2016000024A/es unknown
- 2016-01-20 CL CL2016000143A patent/CL2016000143A1/es unknown
- 2016-02-09 CR CR20160067A patent/CR20160067A/es unknown
- 2016-08-17 HK HK16109836.1A patent/HK1221649A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102243349B1 (ko) | 2021-04-21 |
| PE20160212A1 (es) | 2016-05-09 |
| ES2648913T3 (es) | 2018-01-08 |
| CL2016000143A1 (es) | 2016-06-24 |
| SG11201600218SA (en) | 2016-02-26 |
| CN105407877B (zh) | 2019-05-07 |
| CR20160067A (es) | 2016-04-01 |
| TW201601721A (zh) | 2016-01-16 |
| KR20160037967A (ko) | 2016-04-06 |
| HK1221649A1 (zh) | 2017-06-09 |
| DOP2016000024A (es) | 2016-03-30 |
| JP2015526498A (ja) | 2015-09-10 |
| PH12016500121A1 (en) | 2016-04-25 |
| EP3027176A1 (en) | 2016-06-08 |
| MY176793A (en) | 2020-08-21 |
| BR112016001822B1 (pt) | 2022-10-18 |
| PH12016500121B1 (en) | 2016-04-25 |
| BR112016001822A2 (pt) | 2017-08-01 |
| EP3027176B1 (en) | 2017-08-23 |
| WO2015014766A1 (en) | 2015-02-05 |
| WO2015015062A1 (fr) | 2015-02-05 |
| CN105407877A (zh) | 2016-03-16 |
| JP5905165B2 (ja) | 2016-04-20 |
| TWI642435B (zh) | 2018-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR097193A1 (es) | Comprimidos farmacéuticos que comprenden ácido acetilsalicílico y clopidogrel | |
| ES2631980T3 (es) | Formas de dosificación orales farmacéuticas que comprenden dabigatrán etexilato y sus sales farmacéuticamente aceptables | |
| CO2017012362A2 (es) | Formas de dosificación sólida que comprenden palbociclib, un ácido hidrosoluble y un portador farmacéuticamente aceptable y métodos para su produccion y uso | |
| ECSP13012717A (es) | Tableta oralmente desintegradora | |
| BR112013006932A2 (pt) | composto composição farmacêutica e processo para preparar um composto | |
| AR093134A1 (es) | Capsulas con envoltura del nucleo | |
| AR089666A1 (es) | Formulacion farmaceutica estable para administracion oral que comprende levocetirizina o una de sus sales aceptables desde el punto de vista farmaceutico, y montelukast o una de sus sales aceptables desde el punto de vista farmaceutico | |
| CO2018000991A2 (es) | Tableta | |
| AR103520A1 (es) | Procedimiento de elaboración de pellets entéricos que contienen un inhibidor de la bomba protónica y composiciones farmacéuticas multiparticuladas que los contienen | |
| JP2015518469A5 (es) | ||
| RO128004A3 (ro) | Compoziţie farmaceutică cu eliberare prelungită a trimetazidinei | |
| CY1120746T1 (el) | Παιδιατρικο μασωμενο δισκιο που περιεχει αντιικο παραγοντα και μεθοδος για την παρασκευη του | |
| RU2013123066A (ru) | Способ биоинкапсуляции лекарственных препаратов группы цефалоспоринов | |
| RU2013125050A (ru) | Способ биоинкапсуляции лекарственных препаратов группы цефалоспоринов | |
| RU2013122830A (ru) | Способ биоинкапсуляции лекарственных препаратов группы цефалоспоринов | |
| RU2013123974A (ru) | Способ биоинкапсуляции лекарственных препаратов группы цефалоспоринов | |
| RU2013122156A (ru) | Способ биоинкапсуляции лекарственных препаратов группы цефалоспоринов | |
| CN302131994S (zh) | 包装盒（宝太安叶酸片31） | |
| RU2013125981A (ru) | Способ биоинкапсуляции лекарственных препаратов группы цефалоспоринов | |
| RU2013122327A (ru) | Способ биоинкапсуляции лекарственных препаратов группы цефалоспоринов | |
| RU2016108623A (ru) | Способ получения калия оротата | |
| RU2013122986A (ru) | Способ биоинкапсуляции лекарственных препаратов группы цефалоспоринов | |
| RU2013123068A (ru) | Способ биоинкапсуляции лекарственных препаратов группы цефалоспоринов | |
| BR112018012915A2 (pt) | co-cristal, método de produção do mesmo, e medicamento contendo co-cristal | |
| TH159929A (th) | สารยับยั้ง dgat2 ใหม่ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |